JB/CALL/MODERNA/110/0.0166/20.09.24 | Market Closed - Swiss Exchange 08:50:00 10/05/2024 pm IST | ||
| 0.32 CHF | -5.88% |
|
| Current month | +18.52% | ||
| 1 month | +28.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/24/10 | 0.32 | -5.88% | 0 |
| 08/24/08 | 0.34 | +6.25% | 0 |
| 06/24/06 | 0.32 | -13.51% | 0 |
| 03/24/03 | 0.37 | +12.12% | 0 |
Delayed Quote Swiss Exchange
Last update May 10, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| MRXEJB | |
| ISIN | CH1280667127 |
| Date issued | 17/08/2023 |
| Strike | 110 $ |
| Maturity | 20/09/2024 (131 Days) |
| Parity | 60 : 1 |
| Emission price | 0.3 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.47 CHF |
|---|---|
| Lowest since issue | 0.09 CHF |
| Spread | 0.01 CHF |
| Spread % | 3.13% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
- Stock Market
- Warrants
- MRXEJB Warrant